Bouche, Gauthier;
Gilbert, Duncan;
Quartagno, Matteo;
Dehbi, Hakim-Moulay;
Merrick, Sophie;
Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar;
Stephens, Richard;
... Langley, Ruth E; + view all
(2025)
Determining the optimal use of approved drugs in oncology.
The Lancet Oncology
, 26
(5)
e282-e294.
10.1016/S1470-2045(25)00037-3.
Preview |
Text
Duncan_Web appendix LO 20250110.pdf - Accepted Version Download (153kB) | Preview |
Preview |
Text
Duncan_Tables RDD 20250110 Revised Clean.pdf - Accepted Version Download (250kB) | Preview |
Preview |
Text
Duncan_Manuscript RDD 20250110 Clean.pdf - Accepted Version Download (387kB) | Preview |
Preview |
Text
Duncan_Figures RDD LO revision 20250110.pdf - Accepted Version Download (528kB) | Preview |
Abstract
Optimising the use of approved drugs requires evidence from post-approval trials that investigate variations of their use. Determining optimal drug use goes beyond the dominant, academic effort to conduct trials to identify effective lower doses of new drugs. Other important therapeutic approaches that use either less, similar, or more drug than the standard dose need testing in clinical trials, to get the most out of these drugs. Trial objectives on survival outcomes vary greatly; some aim for superiority, others for equivalent exposure or non-inferiority. This Personal View aims to inform academic trialists in how to conceive and prioritise questions aimed at determining the optimal use of drugs, taking into account the perspectives of patients, clinicians, and trial funders, to maximise the chances of successful delivery and impact for patients globally.
| Type: | Article |
|---|---|
| Title: | Determining the optimal use of approved drugs in oncology |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/S1470-2045(25)00037-3 |
| Publisher version: | https://doi.org/10.1016/s1470-2045(25)00037-3 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Humans, Neoplasms, Antineoplastic Agents, Drug Approval, Medical Oncology, Clinical Trials as Topic |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10208598 |
Archive Staff Only
 |
View Item |
